ALSN News (online only)
News about the C9ORF72 gene, National ALS Registry and Cytokinetics' experimental drug was reported at the 2012 American Academy of Neurology meeting
Posted on Friday, April 27, 2012 - 10:49, By: Amy Labbe
Among the reports given at the 2012 annual meeting of the American Academy of Neurology, being held April 21-28 in New Orleans, was information about research into amyotrophic lateral sclerosis (ALS).
'Best practices' for treating amyotrophic lateral sclerosis (ALS) were among the presentations at MDA’s 2012 Clinical Conference, held in March
Posted on Friday, April 20, 2012 - 14:07, By: Margaret Wahl
Several experts presented their views of best practices for care of people with ALS at MDA's 2012 Clinical Conference, held in Las Vegas March 4-7.
Best practices outlined in this article include:
ALS research news items on findings related to SOD1 in noninherited ALS, toxic SOD1 in ALS-affected tissue, and NIPA1 repeat expansions in ALS
Posted on Friday, April 13, 2012 - 06:00, By: Amy Labbe
SOD1 causes toxicity in some familial and some sporadic ALS
In some people with bulbar-onset sporadic ALS, changes to the SOD1 protein cause the same toxicity as is generated by mutated SOD1 protein in the familial (inherited) form of the disease, a team of researchers has reported.
Transplantation of stem cells into the spinal cords of 12 people with ALS has proven safe and well-tolerated, with no long-term complications
Posted on Wednesday, April 4, 2012 - 06:00, By: Amy Labbe
Neuralstem's spinal cord stem cells, and the surgical technique used to transplant them, proved to be safe and well-tolerated in a phase 1 clinical trial in 12 people with amyotrophic lateral sclerosis (ALS). Although the trial wasn't designed to show efficacy, one participant showed signs of clinical improvement.
A webinar hosted by ALS TDI reviews the biotech's development of TDI 132 (Gilenya), a drug that modulates the immune system
Posted on Friday, March 23, 2012 - 12:51, By: Amy Labbe
An overview of the development of TDI 132 for use in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) was the topic of a webinar hosted March 12, 2012, by the nonprofit biotech ALS Therapy Development Institute (ALS TDI) of Cambridge, Mass.
As progress continues in drug discovery and development at the ALS Therapy Development Institute, MDA's Augie's Quest provides $2 million more in support
Posted on Monday, March 5, 2012 - 06:00, By: Amy Labbe
MDA has extended its strategic research partnership with the ALS Therapy Development Institute (ALS TDI) through 2012 and awarded a $2 million grant to support the nonprofit biotech's continued efforts to develop treatments for ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).
ALS research update on findings related to abnormal functioning of mitochondria, cellular energy production and metabolism
Posted on Friday, February 24, 2012 - 15:01, By: Amy Labbe
Below are highlights of two recent studies in ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).
ALS
- Press Release: MDA's National ALS Awareness Month Series Highlights Emotional, Personal Stories
- ALS Research Briefs: News from 2012 AAN Conference
- MDA 2012 Clinical Conference Report: ALS Best Practices
- ALS Research Briefs: SOD1, Repeat Expansions
- Press Release - Press Release: Long-Distance Swimmer Joins Elite Group and Helps Fund Research through Augie's Quest
- MDA 2012 Conference Report: Targeted Therapies
- Neuralstem Phase 1 Stem Cell Trial Shows Safety, Possible Efficacy
- Press Release - Press Release: Artwork by Indiana Artist Accepted into MDA Art Collection
- ALS TDI Webinar: TDI 132 Project Overview
- Press Release - Press Release: Bash for Augie's Quest Exceeds Expectations
All of contents copyright 2012 MDA All rights reserved.
